Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes

Myasthenia Gravis Clinical Trial

— MYaEX  

Official title:

Barriers and Facilitators to Exercise for Individuals With Autoimmune Myasthenia Gravis, Congenital Myasthenic Syndrome or Lambert-Eaton Myasthenic Syndrome in France: a Descriptive, Cross-sectional Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05408702
• Other study ID #: MYaEX
• Status: Completed
• Start date: November 12, 2021
• Est. completion date: May 15, 2022

Study information

• Verified date: June 2022
• Source: Institut de Myologie, France
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

A few recent observational studies show that despite the lack of clear recommendations, many individuals with myasthenia participate in exercise. However, no link has been found between exercise and the severity of myasthenia symptoms, measured by the Muscle Myasthenia Score or the Myasthenia Gravis Composite Score. This suggests that there are other factors that may limit or prevent some individuals from being active, or factors which may facilitate participation in exercise.

Studies in other diseases have shown that there are internal (beliefs, motivation, etc.) and external (cost, accessibility, etc.) factors unrelated to the disease which may play a role in exercise participation.

The aim of this study is to identify factors that facilitate or limit exercise in individuals with autoimmune myasthenia gravis, congenital myasthenia syndrome and Lambert-Eaton syndrome.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 500
• Est. completion date: May 15, 2022
• Est. primary completion date: May 15, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• at least 18 years old

• confirmed diagnosis of MG or SMC or LEMS

• Live in France or its territories

• Provide consent

Exclusion Criteria:

-

Related Conditions & MeSH terms

• Congenital Myasthenic Syndrome
• Lambert-Eaton Myasthenic Syndrome
• Muscle Weakness
• Myasthenia Gravis
• Myasthenic Syndromes, Congenital
• Syndrome

Locations

Country	Name	City	State
France	Online Questionnaire	Paris

Sponsors (2)

Lead Sponsor	Collaborator
Institut de Myologie, France	Association Française contre les Myopathies (AFM), Paris

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Barriers and facilitators to exercise		Six months